The interplay of immunotherapy and chemotherapy: harnessing potential synergies

LA Emens, G Middleton - Cancer immunology research, 2015 - AACR
Although cancer chemotherapy has historically been considered immune suppressive, it is
now accepted that certain chemotherapies can augment tumor immunity. The recent …

Immunogenic cell death and DAMPs in cancer therapy

DV Krysko, AD Garg, A Kaczmarek, O Krysko… - Nature reviews …, 2012 - nature.com
Although it was thought that apoptotic cells, when rapidly phagocytosed, underwent a silent
death that did not trigger an immune response, in recent years a new concept of …

Systems biology of cisplatin resistance: past, present and future

L Galluzzi, I Vitale, J Michels, C Brenner… - Cell death & …, 2014 - nature.com
The platinum derivative cis-diamminedichloroplatinum (II), best known as cisplatin, is
currently employed for the clinical management of patients affected by testicular, ovarian …

[HTML][HTML] Classification of current anticancer immunotherapies

L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué… - Oncotarget, 2014 - ncbi.nlm.nih.gov
During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …

Molecular mechanisms of ATP secretion during immunogenic cell death

I Martins, Y Wang, M Michaud, Y Ma… - Cell Death & …, 2014 - nature.com
The immunogenic demise of cancer cells can be induced by various chemotherapeutics,
such as anthracyclines and oxaliplatin, and provokes an immune response against tumor …

Precision medicine for metastatic breast cancer—limitations and solutions

M Arnedos, C Vicier, S Loi, C Lefebvre… - Nature reviews Clinical …, 2015 - nature.com
The development of precision medicine for the management of metastatic breast cancer is
an appealing concept; however, major scientific and logistical challenges hinder its …

Trial watch: IDO inhibitors in cancer therapy

J Le Naour, L Galluzzi, L Zitvogel, G Kroemer… - …, 2020 - Taylor & Francis
ABSTRACT Indoleamine 2, 3-dioxygenase 1 (IDO1) catalyzes the first, rate-limiting step of
the so-called “kynurenine pathway”, which converts the essential amino acid L-tryptophan …

Chemoimmunotherapy: reengineering tumor immunity

G Chen, LA Emens - Cancer Immunology, Immunotherapy, 2013 - Springer
Cancer chemotherapy drugs have long been considered immune suppressive. However,
more recent data indicate that some cytotoxic drugs effectively treat cancer in part by …

Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists

T Yamazaki, D Hannani, V Poirier-Colame… - Cell Death & …, 2014 - nature.com
Immunogenic cell death induced by anticancer chemotherapy is characterized by a series of
molecular hallmarks that include the exodus of high-mobility group box 1 protein (HMGB1) …

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer

L Senovilla, E Vacchelli, J Galon, S Adjemian… - …, 2012 - Taylor & Francis
Solid tumors are constituted of a variety of cellular components, including bona fide
malignant cells as well as endothelial, structural and immune cells. On one hand, the tumor …